Latest Insider Transactions at Surface Oncology, Inc. (SURF)
This section provides a real-time view of insider transactions for Surface Oncology, Inc. (SURF). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Surface Oncology, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Surface Oncology, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 28
2020
|
Jessica Fees Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,895
+2.32%
|
$19,580
$4.21 P/Share
|
|
Oct 14
2020
|
Robert W. Ross Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,000
-3.81%
|
$40,000
$10.05 P/Share
|
|
Sep 01
2020
|
Eco R1 Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
332,780
-6.61%
|
$2,329,460
$7.14 P/Share
|
|
Mar 01
2020
|
Alison Oneill Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+50.0%
|
-
|
|
Apr 23
2018
|
Fil LTD |
BUY
Conversion of derivative security
|
Direct |
886,716
+50.0%
|
-
|
|
Apr 23
2018
|
Atlas Venture Fund Ix, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
100,000
+2.11%
|
$1,500,000
$15.0 P/Share
|
|
Apr 23
2018
|
Atlas Venture Fund Ix, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
3,181,817
+41.18%
|
-
|
|
Apr 23
2018
|
Novartis Institutes For Bio Medical Research, Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
766,666
+16.26%
|
$11,499,990
$15.0 P/Share
|
|
Apr 23
2018
|
Novartis Institutes For Bio Medical Research, Inc. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
3,181,816
+36.11%
|
-
|